AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates ...

Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca PLC ...

AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and ...

AstraZeneca PLC AZN shares rallied 1.33% to £117.20 Thursday, on what proved to be an all-around great trading session for ...

We recently compiled a list of the 10 Best Growth Stocks To Buy According To George Soros. In this article, we will look at ...

The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and ...

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...